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Abstract
Background: Many participants in microbicide trials remain uninfected despite ongoing exposure to HIV-1. Determining the
emergence and nature of mucosal HIV-specific immune responses in such women is important, since these responses may
contribute to protection and could provide insight for the rational design of HIV-1 vaccines.
Methods and Findings: We first conducted a pilot study to compare three sampling devices (Dacron swabs, flocked nylon
swabs and Merocel sponges) for detection of HIV-1-specific IgG and IgA antibodies in vaginal secretions. IgG antibodies
from HIV-1-positive women reacted broadly across the full panel of eight HIV-1 envelope (Env) antigens tested, whereas IgA
antibodies only reacted to the gp41 subunit. No Env-reactive antibodies were detected in the HIV-negative women. The
three sampling devices yielded equal HIV-1-specific antibody titers, as well as total IgG and IgA concentrations. We then
tested vaginal Dacron swabs archived from 57 HIV seronegative women who participated in a microbicide efficacy trial in
Southern Africa (HPTN 035). We detected vaginal IgA antibodies directed at HIV-1 Env gp120/gp140 in six of these women,
and at gp41 in another three women, but did not detect Env-specific IgG antibodies in any women.
Conclusion: Vaginal secretions of HIV-1 infected women contained IgG reactivity to a broad range of Env antigens and IgA
reactivity to gp41. In contrast, Env-binding antibodies in the vaginal secretions of HIV-1 uninfected women participating in
the microbicide trial were restricted to the IgA subtype and were mostly directed at HIV-1 gp120/gp140.
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Introduction
Only approximately one in twenty to one in two thousand
unprotected sexual encounters with an HIV-1-infected partner
leads to systemic HIV-1 infection in the recipient [1,2]. There is
evidence, though, that exposures to HIV-1 that fail to establish
infection can still exert immunological effects. For example, HIV-
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1-specific T cells have been detected in highly HIV-1-exposed
individuals who remain seronegative [3–13]. Some studies have
also found mucosal HIV-1-specific neutralizing IgA in the
cervicovaginal lavage and seminal fluid of HIV-1-negative
individuals with HIV-1-infected partners [11,14–17]. Such
immunological responses may serve as markers of prior HIV-1
exposure. Risk status (i.e. level of HIV-1 exposure) is an important
consideration when recruiting subjects for efficacy trials of HIV-1
prevention strategies – the lower the population risk of HIV-1
infection, the larger the study cohorts must be to conclusively test
effectiveness. The presence of HIV-1-specific immunity at a site of
potential HIV-1 transmission might also confer some protection
from infection [18]. Understanding such immune responses could
be of value for HIV-1 vaccine design.
HIV-1-specific antibody titers are in general easier to measure
than HIV-1-specific T cell function, but there is little clear
guidance regarding the optimal specimen types and sampling
devices for the assessment of mucosal antibodies in HIV-1 vaccine
and microbicide clinical trials. Cervicovaginal lavage (CVL) has
been used for the quantification of proteins in genital secretions.
However, CVL sampling is more complicated than swabbing, and
the dilution of mucosal secretions and the resulting variability in
recovered sample volumes can decrease the sensitivity of protein
detection and pose a challenge for data interpretation [19–21].
Therefore in this study, we compared three direct vaginal
sampling devices not requiring a lavage: Dacron swabs, flocked
nylon swabs and Merocel sponges. Using a cohort of five HIV-
positive and five HIV-negative women in Seattle, we determined
total IgG and IgA concentrations obtained from each device, and
then compared antibody reactivity to a panel of eight HIV-1 Env
antigens with an HIV-1-specific binding antibody multiplex assay,
previously utilized for both serum/plasma and mucosal specimens
[22–25]. We then examined HIV-1-specific antibody responses in
swabs obtained from African women participating in the control
arm of the HPTN 035 microbicide trial, a Phase IIb study
designed to assess the effectiveness of 0.5% PRO2000 gel and
BufferGel for the prevention of HIV-1 infection [26]. We found
HIV-1-specific IgA, but not IgG, antibodies in the vaginal
secretions of nine of 57 HPTN 035 participants. These mucosal
HIV-1-specific IgA antibodies could contribute to protection in
these women or be a marker of another protective function; thus,
defining mucosal HIV-specific antibodies in future microbicide
trials should be of major interest to the HIV prevention field.
Methods
Clinical Cohorts and Ethical Approval
Two cohorts of women were enrolled in this study following
review and all protocols were approved by the Fred Hutchinson
Cancer Research Center Institutional Review Board, Duke
University Medical Center IRB, and local IRBs at each of the
HPTN 035 sites. All participants gave written informed consent to
be a part of the study. The Seattle cohort included five HIV-
uninfected women at low risk for HIV-1 infection and five women
Figure 1. Total and HIV-1-specific IgG and IgA in vaginal secretions do not differ by sampling device or timepoint in the same
women. (A) Dacron swabs, flocked swabs, and Merocel sponges were collected from 5 HIV-1 infected (colored circles) and 5 HIV uninfected (grey
triangles) women and the eluate was analyzed for total IgG (left) and total IgA (right). Symbols represent the average of two collection time points
spaced one hour apart, for each woman and sampling device. For HIV-1 infected women, colors indicate specific individuals. (B) Samples from the first
time point (filled circles) and one hour later (open circles) from the 5 HIV-1 infected women were analyzed for gp41-specific IgG (left) and IgA (right)
activity, calculated as antigen-specific mean fluorescence intensity (MFI)/ng ml21 total IgG or IgA. Colors indicate specific individuals. The box-and-
whisker plots represent median, 25th and 75th percentiles, and range.
doi:10.1371/journal.pone.0101863.g001
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with HIV-1 clade B infection who were on antiretroviral treatment
(average blood CD4 count 837/ml). The African cohort comprised
a total of 58 participants in the control, condom-use-only, arm of
the microbicide trial HPTN 035 (ClinicalTrials.gov registration ID
NCT00074425). Vaginal Dacron swabs from approximately 10
women from six HPTN 035 sites were included for analysis:
Blantyre and Lilongwe, Malawi; Durban and Hlabisa, South
Africa; and Harare and Chitungwiza, Zimbabwe. One of the 58
women was found to be clade C HIV-1 seropositive during the
trial and is included here as a positive control. The demographics
of the HPTN 035 study participants, the study protocol and the
results of the clinical study are described elsewhere [26,27].
Vaginal smears were Gram stained for bacterial vaginosis (BV)
diagnosis by Nugent scoring. Gram stains with a Nugent score of
4–6 or $7 were classified as signifying abnormal flora or BV,
respectively.
Swab collection and processing in the Seattle cohort
In the Seattle cohort, three types of swabs were used for the
collection of vaginal secretions: Dacron polyester-tipped swabs
(Fisher Scientific Cat. No. 23-400-122), flocked nylon swabs
(Copan Diagnostics; Fisher Scientific Cat. No. 23-600-957) and
Merocel sponges (Merocel Eye Spears, Beaver-Visitec Interna-
tional, Item No. 400101). Six swabs were taken from each of five
HIV-1-infected and five HIV-uninfected women during two
sessions that were spaced one hour apart. Three swabs, one of
each type, were collected in each session. Half of the women were
randomly assigned to begin session 1 with Dacron swabs followed
by flocked swabs; the other half began session 1 with flocked swabs
followed by Dacron swabs. This swab order was reversed in session
2. In both sessions, Merocel sponges were the third and last sample
type obtained. Swabs were placed into the posterior vaginal fornix
until visibly saturated, but never longer than 1 minute. Swabs
were immediately placed into 500 ml of elution buffer (cold
phosphate-buffered saline (PBS) containing 1% protease inhibitor
cocktail (Calbiochem Set I), 10% Igepal (Sigma) and 0.25% bovine
serum albumin (Sigma)). After transport on ice to the laboratory,
secretions were eluted on the same day. Swabs or Merocel sponges
were transferred into a pre-chilled 0.45 mm SPIN-X filter (Corning
Life Sciences). Swab or sponge handles were clipped off, the
transport buffer was transferred to the SPIN-X filters, and the
SPIN-X filters were spun at 13,0006g for 15 min at 4uC. 300 ml of
elution buffer were added, the SPIN-X filters were incubated on
ice for 5 min, and spun at 13,0006g for 30 min at 4uC. Filter and
sponges were removed and discarded. Eluates were distributed at
100 ml per vial and stored at 280uC until assayed.
Swab collection and processing in HPTN 035
In HPTN 035, vaginal Dacron swabs were collected as
described previously [27]. In brief, during a quarterly pelvic
exam, a Dacron swab was applied to the posterior fornix of the
vagina to saturate the tip with fluid and then placed in a cryovial
containing 400 ml of PBS. The cryovials were stored at 280uC at
the sites and shipped to the Microbicide Trials Network (MTN)
Network Laboratory after the primary study results were available
[26]. Swabs were thawed on wet ice, vortexed, and compressed
against the side of the tube to elute secretions. Swabs were
removed and placed upside down in a new tube and centrifuged at
7006g for 10 min at 4uC to elute remaining secretions. Eluates of
both tubes were combined, using 200 ml of PBS for rinsing. The
combined eluate was centrifuged again to pellet particles. Eluates
(approximately 350 ml total) were stored in aliquots at280uC until
assayed.
Figure 2. HIV-1 infection induces a broader range of HIV-1 Env-
specific IgG than IgA antibodies in vaginal secretions. Vaginal
secretions were collected from 5 HIV-1 infected women and analyzed
for IgG (A–B) and IgA (C–D) binding to the indicated HIV-1 Env antigens.
Antigens not specified as Clade C or consensus (Con6 and ConS) are
derived from Clade B viruses. (A) Average HIV-1 antigen-specific IgG
activity from the combination of the three sampling devices and two
time points, calculated as antigen-specific MFI/ng ml21 total IgG. Black
symbols represent negative responses and colored symbols indicate
Mucosal HIV-1-Binding IgA in HIV-1-Negative Women
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e101863
Multiplex assay for detection of HIV-1-binding antibodies
The HIV-1 binding antibody multiplex assay has been
previously described [23–25,28–30]. Briefly, HIV-1 antigens were
conjugated to polystyrene beads (Bio-Rad) and binding of IgG or
IgA in the eluates to the bead-conjugated HIV-1 antigens was
detected by mouse anti-human IgG-PE (Southern Biotech) or goat
anti-human IgA-PE (Jackson Immunoresearch). To measure HIV-
1-specific IgA, eluates were first depleted of IgG using Protein G
high-performance MultiTrap plates (General Electric) according
to the manufacturer’s instructions. After incubation of beads and
eluates, the beads were washed and acquired on a Bio-Plex 200
instrument (Bio-Rad). HIV-1-specific binding antibodies for each
antigen were measured as Mean Fluorescence Intensity (MFI).
Total IgG and IgA antibody measurements for calculating specific
activity were performed using a Bio-Plex Pro Human Isotyping 7-
plex panel (Bio-Rad) according to the manufacturer’s instructions.
Positivity calls per HIV-1 antigen per antibody isotype were
based on preset criteria determined from HIV-1 negative samples
in the Seattle cohort and were consistent with historical positivity
criteria for mucosal responses. An HIV-1-specific antibody
response was considered positive if it met the positivity criteria
for both MFI and specific activity. Positive MFI responses were
defined as greater than the mean MFI plus 5 standard deviations
of the antigen with the highest background among the 30 samples
taken from the five uninfected women in Seattle. To account for
subject-to-subject variation in fluid collected (including levels
affected by timing of the menstrual cycle and contraceptive use),
MFI values were normalized to total IgG or IgA and computed as
specific activity (antigen specific MFI/ng ml21 total IgG or IgA).
All total antibody measurements were assesed in samples diluted
1:3 in assay diluent (Bio-Rad). Positive specific activity responses
were defined as greater than the mean plus five standard
deviations of the specific activities measured in the five seroneg-
ative individuals in the Seattle cohort.
Reagents for antibody measurements
Antibody responses were determined for the following antigens:
Clade B gp41 Immunodominant epitope tetramer (gp41 ID
epitope) (Biotin -CRVLAVERYLRDQQLLGIWGCSGKLICT-
TAVPWNASWSNKSLNKI), 2F5 mAb epitope tetramer (Biotin-
GGGQQEKNEQELLELDKWASLWN), clade B MPER tetra-
mer (MPR.03) (KKKNEQELLELDKWASLWNWFDITNWL-
WYIRKKK-Biotin) (containing the linear binding sites for MPER
neutralizing antibodies), and clade C MPER (MPR.C956)
tetramer (Biotin-NEQELLELDKWASLWNWFNITNWLW) (de-
rived from a clade C sequence and containing the linear binding
sites MPER neutralizing antibodies (tetramers provided by Dr.
Anthony Moody, Duke Human Vaccine Institute; [31,32]);
Consensus gp120 Env (Con6 gp120), clade C gp140 Env trimer
(1086 Trimer) (a transmitted/founder sequence envelope sequence
from a clade C infected patient from Malawi, [33] and a Group M
consensus gp140 Env (ConS gp140) [34–36] (envelope proteins
provided by Drs. Barton Haynes and Larry Liao, Duke Human
Vaccine Institute). The consensus sequence for Group M is central
to all circulating clades, and reacts well with sera from all subtypes
[34–36] and was found to be similar to autologous envelopes in
detection of the initial antibody response in acute infections [23].
Clade B HIV-1MN recombinant gp41 protein was commercially
available (Immunodiagnostics). Positive controls included titration
of purified pooled HIV-1+ immunoglobulin (HIVIG), 2F5
monoclonal antibody (mAb) IgA, 2F5 mAb IgG, 4E10 IgG, b12
IgG (all from Polymun Scientific), b12 IgA (kindly provided by
Drs. Ann Hessell and Dennis Burton, The Scripps Research
Institute), and 7B2 mAb IgG (Dr. James Robinson, Tulane
University). Negative controls included matched seronegative
samples, bare tetramers, blank beads, and normal human serum
(NHS) (Sigma).
Statistical analysis
For the Seattle pilot cohort, ANOVA with fixed effects was
applied to assess the influence of swab type, time point of sample
collection and subject HIV serostatus on log10 total IgG and IgA
concentrations. ANOVA with fixed effects was also used to assess
the influence of swab type and time point of sample collection on
log10 HIV-1-specific IgG activities. For the HPTN 035 cohort, the
effect of study country or vaginal flora Nugent scoring on the
presence of vaginal HIV-1-reactive IgA antibodies was tested by
Chi-square test or Fisher’s exact test, respectively.
Results
Comparison of three sampling devices for measuring
total and HIV-1 envelope-specific IgG and IgA antibodies
in vaginal secretions
Dacron polyester-tipped swabs, flocked nylon swabs and
Merocel sponges were obtained from 5 HIV-1 infected women
and 5 HIV uninfected women (Seattle cohort). Six samples were
taken from each woman, one of each type in a first session, and
one of each type again one hour later. The amount of total IgG
and IgA collected from each sampling device did not differ by
device type (p= 0.7 for IgG; p= 0.8 for IgA) or time point of
sampling (ANOVA with fixed effects, p = 0.6 for IgG; p= 0.4 for
IgA) (Figure 1A). The total amount of IgG also did not differ by
HIV serostatus (p = 0.5), however the total amount of IgA was
significantly higher in the HIV-negative subjects (mean log10
4.24 ng/ml60.65 versus log10 3.9160.48; p = 0.03) (Figure 1A).
In these samples, we additionally examined HIV-1-specific activity
against a panel of eight Env antigens covering multiple epitopes in
gp41, the gp41 membrane proximal external region (MPER),
gp120 and gp140. HIV-1-specific IgG activity for each antigen did
not differ by device type or time point of sampling (all F-test p
values.0.05). There were too few positive values to statistically
evaluate differences in HIV-1-specific IgA activity. Specific
activities for gp41-binding IgG (Figure 1B, left panel) and IgA
(Figure 1B, right panel) are shown as a representative antigen. In
conclusion, Dacron swabs, flocked swabs and Merocel sponges
appear equally suitable for measuring total immunoglobulins and
HIV-1-specific IgG and IgA in vaginal secretions.
Comparison of HIV-1 envelope-specific IgG to IgA
responses in the vagina of HIV-1 infected women
HIV-1 infection induced a broad range of envelope-specific IgG
responses in the vaginal mucosa of the five HIV-1 infected women
in Seattle (Figure 2A and B). These responses favored gp41 and
the gp41 ID epitope (5/5 women tested positive); however
significant responses were also seen against the gp120 antigen
Con6 gp120 (3/5), and the gp140 antigens Clade C 1086 trimer
(4/5) and ConS gp140 (4/5). Only one woman had IgG antibodies
positive responses, with the colors corresponding to specific individ-
uals. Samples that did not meet the positivity criteria are displayed at
zero for specific activity. (B) Percentage of women with positive IgG
binding. (C) Average HIV-1 antigen-specific IgA activity, calculated as
antigen-specific MFI/ng ml21 total IgA. (D) Percentage of women with
positive IgA binding.
doi:10.1371/journal.pone.0101863.g002
Mucosal HIV-1-Binding IgA in HIV-1-Negative Women
PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e101863
against the three membrane proximal external region (MPER)
antigens. IgA responses were seen at a lower frequency (Figure 2C
and D). HIV-1-specific IgA activity was predominantly directed
toward gp41 (4/5 women) and the gp41 ID epitope (2/5). One
woman had gp140-specific IgA against the Clade C 1086 trimer
and ConS gp140 antigens. None of the women had vaginal IgA
antibodies specific to the three MPER antigens or to gp120. None
of the 30 specimens taken from the five HIV uninfected women
had IgG or IgA antibodies to any of the tested HIV-1 antigens (not
shown). These data indicate that the HIV-1 binding antibody
multiplex assay detects vaginal HIV-1 specific antibodies in a
highly specific manner, and that the vaginal IgA response to HIV-
1 infection is markedly narrower than the vaginal IgG response.
HIV-1 envelope-specific binding antibody responses in
the vaginal mucosa of African women participating in
the HPTN 035 microbicide trial
Having demonstrated the specificity of our assay to detect HIV-
1-reactive antibodies in vaginal secretions, as well as the suitability
of Dacron swabs to obtain secretions for performing these
measurements, we next examined vaginal HIV-1-specific antibody
responses in a cohort of African women enrolled in the HPTN 035
Phase IIb clinical trial. Of the 58 women we analyzed from this
cohort, 57 women remained uninfected while one woman
seroconverted. Vaginal secretions from the sole seroconverter
contained HIV-1-specific IgG (Figure 3A) but not IgA antibodies
(Figure 3B). Pooled HIV+ immunoglobulin, as well as the control
IgG antibodies 4E10 and 2F5, showed binding to their respective
antigens (Figure 3A). Likewise, the control IgA antibodies 7B2,
b12 and 2F5 bound their respective antigens (Figure 3B).
None of the 57 HIV uninfected women had HIV-1 envelope-
reactive vaginal IgG antibodies (Figure 3C). Nine women
(15.8%) had HIV-1 envelope-reactive IgA antibodies in their
vaginal secretions (Figure 3D and E). IgA antibodies to both
Con6 gp120 and ConS gp140 were detected in six women
(10.5%), and IgA antibodies from two additional women were
specific for the gp41 ID epitope (3.5%). Secretions from one of
these two women also reacted to the MPR.03 epitope (1.8%).
Vaginal secretions from the ninth woman reacted to the 2F5
epitope (1.8%). These data indicate the presence of HIV-1
envelope-reactive IgA but not IgG antibodies in vaginal secretions
of ,16% of African women participating in the control arm of the
Figure 3. HIV-1 exposure elicits anti-Env IgA but not IgG
antibodies in the vaginal mucosa. Vaginal Dacron swabs were
collected from 57 HIV seronegative women enrolled in the HPTN 035
microbicide trial and analyzed for IgG (C) and IgA (D–E) binding to the
indicated HIV-1 Env antigens. (A) Positive IgG controls. Binding of
purified pooled HIV-1+ immunoglobulin (HIVIG), 4E10 monoclonal IgG
(50 mg/ml), 2F5 monoclonal IgG (16 mg/ml) and swabs from an HIV-1
infected HPTN 035 participant (HIV+) in mean fluorescent intensity (MFI).
(B) Positive IgA controls. Binding of 7B2 monoclonal IgA (1 mg/ml), b12
monoclonal IgA (20 mg/ml) and 2F5 monoclonal IgA (1 mg/ml) in MFI.
Lack of IgA binding from an HIV-1 infected HPTN 035 participant (HIV+)
is also shown. (C) HIV-1 antigen-specific IgG activity, calculated as
antigen-specific MFI/ng ml21 total IgG, in 57 women participating in
HPTN 035. One additional HIV-1 infected HPTN 035 participant (HIV+) is
also shown. (D) HIV-1 antigen-specific IgA activity, calculated as
antigen-specific MFI/ng ml1 total IgA. For the 57 HPTN 035 women
(squares), black symbols signify negative responses and colored
symbols signify positive responses, with colors indicating specific
women. Samples that did not meet the positivity criteria are displayed
at zero for specific activity. One additional HIV-1 infected HPTN 035
participant (HIV+) is also shown (open circles). (E) Percentage of the 57
HPTN 035 women with positive IgA binding.
doi:10.1371/journal.pone.0101863.g003
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HPTN 035 microbicide trial. While antibodies from each woman
reacted to only one or two HIV-1 antigens, collectively, antibodies
from the nine IgA-positive women reacted to five of the eight
HIV-1 envelope antigens tested.
Relationship of vaginal HIV-1-reactive IgA antibodies in
HIV-negative women to HPTN 035 study site and country
and to bacterial vaginosis
Particularly high HIV-1 incidence rates have been reported for
South Africa, with a reported prevalence of 21.1% in young
women aged 20–24 (2008), and a prevalence up to 39.5% in
pregnant women in KwaZulu Natal (2010) [37,38]. Consequently,
the likely higher HIV-1 exposure rates in South Africa could lead
to the emergence of vaginal HIV-1-reactive IgA antibodies more
often than in countries with lower HIV-1 incidence. We thus
investigated the geographic distribution of the nine women with
vaginal HIV-1-reactive IgA antibodies were seen. In South Africa,
3/9 women in Durban (33.3%) and 1/9 women in Hlabisa
(11.1%); in Zimbabwe, 3/10 women in Chitungwiza (30%) and 0/
10 women in Harare (0%); and in Malawi, 1/9 women in
Lilongwe (11.1%) and 1/10 women in Blantyre (10%), were IgA
positive. Thus, 22.2% of South African, 15% of Zimbabwean and
10.5% of Malawian women tested positive for vaginal HIV-1-
reactive IgA antibodies, with no significant differences between
countries (Chi square p= 0.62).
We also investigated whether a relationship between vaginal
HIV-1-reactive IgA status and bacterial vaginosis (BV) existed.
Twenty of the 57 HIV-1 uninfected HPTN 035 women had
abnormal vaginal flora (Nugent score 4–6) and seven had BV
(Nugent score$7). Among the nine women with HIV-1-reactive
IgA antibodies, two had abnormal flora and one had BV, while 18
of the other 48 women had abnormal flora (Fisher’s exact p = 0.47)
and six had BV (p= 1.0). Thus, abnormal vaginal flora and
bacterial vaginosis did not correlate with the presence of vaginal
HIV-1 envelope-reactive IgA antibodies.
Discussion
Our study confirms a number of prior reports of HIV-1-specific
IgA in the genital tracts of HIV-1-exposed seronegative women
[6,14,17,39–42]. Between 38% and 82% of highly exposed
seronegative (HESN) women [6,41,42] have been reported to
have genital HIV-1-specific IgA, although one study of uninfected
sex workers from the Gambia failed to detect any vaginal antibody
responses against HIV-1 [43]. In our study, 9/57 (15.8%) women
had vaginal HIV-1-specific IgA antibodies. Reasons for divergent
frequencies in different studies and cohorts have been discussed
elsewhere [16], but actual exposure rates to HIV-1 should be a
major determinant. It is not surprising that IgA frequencies in our
cohort were at the lower end of the reported range, because
HPTN 035 study subjects [26], including the 57 women we
studied, were not screened for self-reported risk factors such as
frequent unprotected sex, a known HIV-infected partner and/or
commercial sex work. Thus, HPTN 035 study women did not fit
the HESN definition [44,45] and their risk profile was on average
likely lower than that of HESN individuals. Moreover, sample
collection and storage methods, in addition to the conservative,
two-tiered definition of antibody positivity, may have contributed
to the relatively low frequency of HPTN 035 women with positive
HIV-1-specific vaginal IgA. Additionally the hormonal cycle can
influence both IgG and IgA antibody levels [46,47]. One
limitation of our study with HPTN 035 samples was that due to
study size and inclusion criteria (,3099 female participants with
some contraceptive use) the sample collections were not synchro-
nized around the participant’s menstrual cycle. We controlled for
antibody levels among participants in our analyses by factoring in
total antibody levels along with the HIV-1 specific antibody
calculations.
Nevertheless, vaginal swabs from ,16% of the uninfected
HPTN 035 women we tested were positive for HIV-1-specific IgA
antibodies, whereas none of the 57 women were positive for HIV-
1-specific IgG antibodies. This indicates that the presence of HIV-
1-specific mucosal IgA could be used as an indicator of HIV-1
exposure in subjects participating in HIV prevention trials [48].
Additionally, our study demonstrated that vaginal swabs routinely
obtained during a microbicide trial and stored frozen for several
years can be used for that purpose. While this was the first time
that HIV-1-specific mucosal antibodies were evaluated in a
microbicide trial, similar studies should be pursued in ongoing
and future trials of topical pre-exposure prophylaxis (PrEP). Of
particular interest will be the question of whether efficacious
topical PrEP, which as of yet has not been developed, might
contribute to a mucosal state of HIV-1-specific immunity by
exposures to microbicide-inactivated HIV-1 and/or by aborting
local infections. This principle has been demonstrated in
macaques [49] and may over time provide an added benefit to
using topical PrEP, i.e., an additional level of resistance through
adaptive immunity. The nature of this immune response in
microbicide-using women would be of major interest to the HIV
vaccine field.
In this context, it is interesting to note that antibody responses in
HIV-1 infected persons are dominated by IgG, whereas HIV-1-
specific IgA appears to be impaired [25,50,51]. In contrast,
exposed uninfected individuals develop nearly exclusively HIV-1-
specific antibodies of the IgA type [16], as also seen in our study
here. Furthermore, we have previously demonstrated that the
initial antibody response to HIV-1 infection is directed to gp41
[23] and that the initial mucosal IgA response (in cervical lavage
and seminal plasma) is also directed to gp41, with limited reactivity
to other regions of the HIV-1 envelope [25]. In the exposed
uninfected HPTN 035 women, however, six of the nine women
with positive HIV-1-specific IgA in the vagina showed reactivity to
gp120 and gp140, whereas only three reacted to gp41 epitopes.
This finding is consistent with our work in another exposed
uninfected cohort (CHAVI 002; United Kingdom and Uganda),
where we detected anti-HIV-1 gp120 IgA, but not IgG, responses
in blood (Shen et al., unpublished). Thus, the results from both
studies, with samples obtained from different geographic locations,
converge on the same notion that HIV-1 gp120-specific IgA are
induced in individuals that are (likely repeatedly) exposed to HIV-
1, but are not part of the initial response to acute HIV-1 infection.
Due to low numbers of women with mucosal HIV-1 specific IgA
responses, we did not have the power to robustly determine if there
was an association between sexual risk factors and the presence of
vaginal HIV-1 IgA. The reasons for this skewing of genital HIV-1-
specific antibody responses in exposed uninfected women toward
the IgA subtype and toward HIV-1 gp120/gp140 remain unclear.
However, these findings emphasize that further study of mucosal
HIV-1-specific IgA responses in exposed uninfected individuals
could uncover clues for purposefully driving a vaccine-induced
response toward protective IgA-mediated mucosal immunity.
One caveat of the current study is that limited sample volume
precluded testing of these mucosal antibodies for specific antiviral
functions. Thus, we were not able to determine if the detected
antibodies can block HIV-1 infection. Further studies comparing
other methods for antibody elutions from wecks [52,53] may
provide improved antibody recovery. Other investigators have
shown that monoclonal HIV-1 gp41-specific IgA antibodies
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derived from highly exposed seronegative individuals can neutral-
ize HIV-1 and inhibit virion transcytosis through epithelial cells
[40,54,55]. It is also encouraging that protection from simian/
human immunodeficiency virus infection in macaques can in
principle be achieved by passive administration of neutralizing and
non-neutralizing HIV-1 inhibitory antibodies to the vagina
[56,57]. Thus, further studies are needed that collect larger
volumes of mucosal fluids to continue investigations into the
antiviral properties of mucosal IgA in HIV-1 exposed uninfected
individuals, such as antibody-mediated movement arrest of HIV-1
in cervical mucus [58], virion capture [30,59] and neutralization
[11,14,16,17].
Evaluation of mucosal immune responses is also crucial to
interpret the findings of HIV-1 vaccine trials. The lack of such
mucosal studies has left us with unanswered questions regarding
the lack of efficacy of the HIV-1 vaccines tested in the Step,
Phambili and HVTN 505 trials [60–63], as well as other potential
correlates of protection conferred by the HIV-1 vaccine tested in
the RV144 trial [64,65]. These trials did not assess mucosal
immune responses largely because of the lack of optimized and
standardized procedures for mucosal specimen harvesting, includ-
ing uncertainty over which specimens and sampling devices are
best for a given research question. This is in part due to the
variability of methods used to collect genital secretions, yielding
different amounts of fluid and leading to sample dilution when
using cervicovaginal lavage [19–21]. We compared three devices
for harvesting undiluted vaginal secretions and found that Merocel
sponges were preferred by clinicians and recovered similar
amounts of total and HIV-1-specific antibodies as compared to
Dacron and flocked nylon swabs. Thus, all three sampling devices
could be used in future vaccine and topical PrEP trials where
measurement of vaginal HIV-1-specific antibodies is desired.
Taken together, we report that genital HIV-1 envelope-specific
antibodies in HIV exposed uninfected women in a large
microbicide trial were predominantly of the IgA isotype.
Strikingly, the epitope specificities of these Env-specific IgA were
predominantly directed to gp120, unlike those IgAs induced in
acute HIV-1 infection that predominantly target gp41 [23,25].
Further study of these responses to determine their usefulness as
markers of HIV-1 exposure as well as their protective potential is
warranted.
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